H-NLVPMVATV-NH2
Ref. 3D-PP49587
Unbestimmte Größe | Nachfragen |
Produktinformation
Peptide H-NLVPMVATV-NH2 is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-NLVPMVATV-NH2 include the following: Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer YU Sawada, H Komori, Y Tsunoda - Oncology , 2014 - spandidos-publications.comhttps://www.spandidos-publications.com/10.3892/or.2013.2941 Procedure for preparing peptide-major histocompatibility complex tetramers for direct quantification of antigen-specific cytotoxic T lymphocytes XH He, LH Xu, Y Liu - World Journal of Gastroenterology: WJG, 2005 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615439/ Combinatorial HLA-peptide bead libraries for high throughput identification of CD8+ T cell specificity X Pan, LC Huang, T Dong , Y Peng, V Cerundolo - Journal of , 2014 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0022175913003608 HLA class I-restricted recognition of an HIV-derived epitope peptide by a human T cell receptor alpha chain having a VÎŽ1 variable segment T Ueno , H Tomiyama, M Fujiwara - European journal of , 2003 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.200324148 Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells SK Saini , T Tamhane, R Anjanappa, A Saikia - Science , 2019 - science.orghttps://www.science.org/doi/abs/10.1126/sciimmunol.aau9039 Dipeptides catalyze rapid peptide exchange on MHC class I molecules SK Saini , H Schuster - Proceedings of the , 2015 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.1418690112 Identificaiton of novel immunogenic human papillomavirus type 16 E7-specific epitopes restricted to HLA-A* 33; 03 for cervical cancer immunotherapy S Kim, HW Chung , HY Kong, JB Lim - Yonsei medical journal, 2017 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122651/ Recruitment of Oligoclonal Viral-Specific T cells to Kill Human Tumor Cells Using Single-Chain Antibody-Peptide-HLA Fusion Molecules R Noy, M Haus-Cohen, K Oved , T Voloshin - Molecular Cancer , 2015 - AACRhttps://aacrjournals.org/mct/article-abstract/14/6/1327/91951 Altered peptide ligands revisited: Vaccine design through chemically modified HLA-A2-restricted T cell epitopes R Hoppes, R Oostvogels , JJ Luimstra - The Journal of , 2014 - journals.aai.orghttps://journals.aai.org/jimmunol/article/193/10/4803/97379 Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue MJ Maeurer , A Necker, RD Salter - journal of cancer, 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.1580 Synthesis and ex vivo profiling of chemically modified cytomegalovirus CMVpp65 epitopes MA Jones , JK Notta, M Cobbold - Journal of Peptide , 2008 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/psc.930 Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins M Speir , A Authier-Hall, CR Brooks , KJ Farrand - Scientific reports, 2017 - nature.comhttps://www.nature.com/articles/s41598-017-14690-5 A novel peptide carrier for efficient targeting of antigens and nucleic acids to dendritic cells M Sioud, G Skorstad, A Mobergslien - The FASEB , 2013 - Wiley Online Libraryhttps://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fj.12-224758 Human Papillomavirus Type 16 E7 Peptide-Directed CD8+ T Cells from Patients with Cervical Cancer Are Cross-Reactive with the Coronavirus NS2 Protein K Nilges, H HoÃËhn, H Pilch, C Neukirch - Journal of , 2003 - Am Soc Microbiolhttps://journals.asm.org/doi/abs/10.1128/jvi.77.9.5464-5474.2003 Peptide-Major Histocompatibility Complex Class I Tetramers with Enhanced Coreceptor Binding Properties Enable Visualization of Low Avidity Leukemia-Associated JJ Melenhorst, P Scheinberg , E Gostick - 2007 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/110/11/1343/73744 Delivery of large heterologous polypeptides across the cytoplasmic membrane of antigen-presenting cells by the Bordetella RTX hemolysin moiety lacking the J Holubova, J Kamanova, J Jelinek, J Tomala - Infection and , 2012 - Am Soc Microbiolhttps://journals.asm.org/doi/abs/10.1128/IAI.05711-11 Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders J Bae, R Smith, J Daley, N Mimura, YT Tai - Clinical Cancer , 2012 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/18/17/4850/283647 Novel Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell J Bae, R Carrasco , AH Lee , R Prabhala , YT Tai - Blood, 2011 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119619166 A modified peptide stimulation method for efficient amplification of cytomegalovirus (CMV)-specific CTLs G Ruan, L Ma, Q Wen , W Luo, M Zhou - Cellular & Molecular , 2008 - nature.comhttps://www.nature.com/articles/cmi200824 Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules FT Ilca, A Neerincx, MR Wills - Proceedings of the , 2018 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.1809465115 Analysis of antigen-specific T-cell responses with synthetic peptides-what kind of peptide for which purpose? F Kiecker, M Streitz, B Ay, G Cherepnev, HD Volk - Human immunology, 2004 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0198885904000539 Dendritic Cells Engineered to Express Defined Allo-HLA Peptide Complexes Induce Antigen-specific Cytotoxic T Cells Efficiently Killing Tumour Cells E Stronen, IW Abrahamsen - Scandinavian , 2009 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-3083.2008.02223.x Peptide-specific CD8+ T-cell evolution in vivo: Response to peptide vaccination with Melan-A/MART-1 E Jager, H Höhn, A Necker, R Förster - journal of cancer, 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.10165 Mutated NPM1 as target for immunotherapy of acute myeloid leukemia DI Van Der Lee, HM Bijen, RS Hagedoorn - Blood, 2017 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119806857 In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells DE Speiser , D Lienard, MJ Pittet - European journal of , 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/1521-4141(200203)32:3%3C731::AID-IMMU731%3E3.0.CO;2-H Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy D Trivedi, RY Williams, RJ O'Reilly, G Koehne - Blood, 2005 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/105/7/2793/20239 Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer D Nobuoka, T Yoshikawa, M Takahashi - Cancer Immunology , 2013 - Springerhttps://link.springer.com/article/10.1007/s00262-012-1366-6 Random screening of proteins for HLA-A* 0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell epitopes recognized in the context of HLA C Pelte, G Cherepnev, Y Wang - The Journal of , 2004 - journals.aai.orghttps://journals.aai.org/jimmunol/article/172/11/6783/80929
Chemische Eigenschaften
Technische Anfrage zu: 3D-PP49587 H-NLVPMVATV-NH2
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.